Floatz logo

azd1390

Childhood Astrocytoma

Children's Oncology GroupPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Childhood Astrocytoma cohort.

Asset / SponsorPhaseRating
Sargramostim
Mayo Clinic
Phase 1CC
Wild-Type Reovirus
Mayo Clinic
Phase 1CC

Same molecule, other indications

azd1390 is also rated in:

glioblastomaDormant
B
Indicative ·
58 / 100
View asset →
brain cancerDormant
CC
Indicative ·
43 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →